Incidence and characteristics of HBV reactivation in hematological malignant patients in south Egypt

World Journal of Gastroenterology

Volumn 19, Issue 37, 2013, Pages 6214-6220

  Elkady, Abeer ^a,b   Aboulfotuh, Sahar ^c   Ali, Elsayed Mostafa ^c   Sayed, Douaa ^d   Abdel Aziz, Nashwa M ^d   Ali, Amany M ^d   Murakami, Shuko ^a   Iijima, Sayuki ^a   Tanaka, Yasuhito ^a  

^a NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

^b SOUTH VALLEY UNIVERSITY   (Egypt)

^c SOHAG UNIVERSITY   (Egypt)

^d ASSIUT UNIVERSITY   (Egypt)

Author keywords

Hepatitis B surface antigen; Hepatitis B virus; Occult infection; Reactivation

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; CYTARABINE; ETOPOSIDE; FARMARABIN; HEPATITIS B CORE ANTIBODY; HEPATITIS B CORE ANTIGEN; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; LIVER ENZYME; MERCAPTOPURINE; METHOTREXATE; PREDNISONE; STEROID; UNCLASSIFIED DRUG; VINCRISTINE; VIRUS DNA;

ACUTE LEUKEMIA; ADULT; AGED; ARTICLE; CANCER THERAPY; CHEMILUMINESCENCE IMMUNOASSAY; DRUG MEGADOSE; EGYPT; ENZYME IMMUNOASSAY; FEMALE; GENOTYPE; HEMATOLOGIC MALIGNANCY; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; PHYLOGENETIC TREE; REAL TIME POLYMERASE CHAIN REACTION; RISK FACTOR; SEROLOGY; VIRUS REACTIVATION;

HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VIRUS; OCCULT INFECTION; REACTIVATION;

AGED; ANTINEOPLASTIC AGENTS; BIOLOGICAL MARKERS; CHILD; CHILD, PRESCHOOL; DNA, VIRAL; EGYPT; FEMALE; GENOTYPE; HEMATOLOGIC NEOPLASMS; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; MALE; PHYLOGENY; RISK FACTORS; TREATMENT OUTCOME; VIRUS ACTIVATION; YOUNG ADULT;

EID: 84885620220     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v19.i37.6214     Document Type: Article

References (27)

1. Lee WM. Hepatitis B virus infection. N Engl J Med 1997; 337: 1733-1745 [PMID: 9392700 DOI: 10.1056/NEJM199712113372406]
2. Freudiger H, Sitavanc R. Reverse seroconversion of hepatitis B in a haemodialysis patient. Nephrol Dial Transplant 2004; 19: 238-241 [PMID: 14671065 DOI: 10.1093/ndt/gfg448]
3. Schnepf N, Sellier P, Bendenoun M, Zini JM, Sanson-le Pors MJ, Mazeron MC. Reactivation of lamivudine-resistant occult hepatitis B in an HIV-infected patient undergoing cytotoxic chemotherapy. J Clin Virol 2007; 39: 48-50 [PMID: 17368969 DOI: 10.1016/j.jcv.2007.01.011]
4. Chakvetadze C, Bani-Sadr F, Le Pendeven C, Lamontagne F, Vincensini JP, Pialoux G. Reactivation of hepatitis B virus replication during peginterferon-ribavirin therapy in an HIV/hepatitis C virus-co-infected patient with isolated antihepatitis B core antibodies. AIDS 2007; 21: 393-394 [PMID: 17255759 DOI: 10.1097/QAD.0b013e328012b5d3]
5. Clark SJ, Creighton S, Horner M, Smith HM, Portmann B, Taylor C, Cramp ME. Reactivation of latent hepatitis B virus infection with HIV-related immunosuppression. Int J STD AIDS 2006; 17: 67-69 [PMID: 16409685 DOI: 10.1258/0956462 06775220612]
6. Bortolotti F, Crivellaro C, Brunetto MR, Cadrobbi P, Bertolini A, Alberti A. Selection of a precore mutant of hepatitis B virus and reactivation of chronic hepatitis B acquired in childhood. J Pediatr 1993; 123: 583-585 [PMID: 8410512 DOI: 10.1016/S0022-3476(05)80956-4]
7. Lowell JA, Howard TK, White HM, Shenoy S, Huettner PC, Brennan DC, Peters MG. Serological evidence of past hepatitis B infection in liver donor and hepatitis B infection in liver allograft. Lancet 1995; 345: 1084-1085 [PMID: 7715341 DOI: 10.1016/S0140-6736(95)90819-6]
8. Nordbø SA, Skaug K, Holter E, Waage A, Brinch L. Reactivation of hepatitis B virus infection in an anti-HBc and anti-HBs positive patient after allogeneic bone marrow transplantation. Eur J Haematol 2000; 65: 86-87 [PMID: 10914949 DOI: 10.1034/j.1600-0609.2000.9l228.x]
9. Chamorro AJ, Casado JL, Bellido D, Moreno S. Reactivation of hepatitis B in an HIV-infected patient with antibodies against hepatitis B core antigen as the only serological marker. Eur J Clin Microbiol Infect Dis 2005; 24: 492-494 [PMID: 15990987 DOI: 10.1007/s10096-005-1355-1]
10. Kitano K, Kobayashi H, Hanamura M, Furuta K, Ueno M, Rokuhara A, Tanaka E, Umemura T, Kiyosawa K. Fulminant hepatitis after allogenic bone marrow transplantation caused by reactivation of hepatitis B virus with gene mutations in the core promotor region. Eur J Haematol 2006; 77: 255-258 [PMID: 16923112 DOI: 10.1111/j.1600-0609.2006.00678.x]
11. Lin PC, Poh SB, Lee MY, Hsiao LT, Chen PM, Chiou TJ. Fatal fulminant hepatitis B after withdrawal of prophylactic lamivudine in hematopoietic stem cell transplantation patients. Int J Hematol 2005; 81: 349-351 [PMID: 15914368 DOI: 10.1532/IJH97.A10411]
12. Hu KQ. Occult hepatitis B virus infection and its clinical implications. J Viral Hepat 2002; 9: 243-257 [PMID: 12081601 DOI: 10.1046/j.1365-2893.2002.00344.x]
13. Ozaslan E, Purnak T. Controversies about occult hepatitis B virus infection. World J Gastroenterol 2009; 15: 4986-4987 [PMID: 19842236 DOI: 10.3748/wjg.15.4986]
14. Raimondo G, Pollicino T, Cacciola I, Squadrito G. Occult hepatitis B virus infection. J Hepatol 2007; 46: 160-170 [PMID: 17112622 DOI: 10.1016/j.jhep.2006.10.007]
15. Sugiyama M, Tanaka Y, Kurbanov F, Maruyama I, Shimada T, Takahashi S, Shirai T, Hino K, Sakaida I, Mizokami M. Direct cytopathic effects of particular hepatitis B virus genotypes in severe combined immunodeficiency transgenic with urokinase-type plasminogen activator mouse with human hepatocytes. Gastroenterology 2009; 136: 652-662. e3 [PMID: 19041311 DOI: 10.1053/j.gastro.2008.10.048]
16. Sugauchi F, Orito E, Ichida T, Kato H, Sakugawa H, Kakumu S, Ishida T, Chutaputti A, Lai CL, Ueda R, Miyakawa Y, Mizokami M. Hepatitis B virus of genotype B with or without recombination with genotype C over the precore region plus the core gene. J Virol 2002; 76: 5985-5992 [PMID: 12021331 DOI: 10.1128/JVI.76.12.5985-5992.2002]
17. Shin IT, Tanaka Y, Tateno Y, Mizokami M. Development and public release of a comprehensive hepatitis virus database. Hepatol Res 2008; 38: 234-243 [PMID: 17877727 DOI: 10.1111/j.1872-034X.2007.00262.x]
18. Hui CK, Cheung WW, Zhang HY, Au WY, Yueng YH, Leung AY, Leung N, Luk JM, Lie AK, Kwong YL, Liang R, Lau GK. Kinetics and risk of de novo hepatitis B infection in HBsAg-negative patients undergoing cytotoxic chemotherapy. Gastroenterology 2006; 131: 59-68 [PMID: 16831590 DOI: 10.1053/j.gastro.2006.04.015]
19. Matsue K, Kimura S, Takanashi Y, Iwama K, Fujiwara H, Yamakura M, Takeuchi M. Reactivation of hepatitis B virus after rituximab-containing treatment in patients with CD20-positive B-cell lymphoma. Cancer 2010; 116: 4769-4776 [PMID: 20597091 DOI: 10.1002/cncr.25253]
20. Francisci D, Falcinelli F, Schiaroli E, Capponi M, Belfiori B, Cecchini E, Baldelli F. Reactivation of hepatitis B virus replication due to cytotoxic therapy: a five-year prospective study. Tumori 2012; 98: 220-224 [PMID: 22677988]
21. Chu CM, Liaw YF. Genotype C hepatitis B virus infection is associated with a higher risk of reactivation of hepatitis B and progression to cirrhosis than genotype B: a longitudinal study of hepatitis B e antigen-positive patients with normal aminotransferase levels at baseline. J Hepatol 2005; 43: 411-417 [PMID: 16006001 DOI: 10.1016/j.jhep.2005.03.018]
22. Romero M, Madejón A, Fernández-Rodríguez C, García-Samaniego J. Clinical significance of occult hepatitis B virus infection. World J Gastroenterol 2011; 17: 1549-1552 [PMID: 21472119 DOI: 10.3748/wjg.v17.i12.1549]
23. Said ZN. An overview of occult hepatitis B virus infection. World J Gastroenterol 2011; 17: 1927-1938 [PMID: 21528070 DOI: 10.3748/wjg.v17.i15.1927]
24. Samal J, Kandpal M, Vivekanandan P. Molecular mechanisms underlying occult hepatitis B virus infection. Clin Microbiol Rev 2012; 25: 142-163 [PMID: 22232374 DOI: 10.1128/ CMR.00018-11]
25. Zaaijer HL, Torres P, Ontañón A, Ponte LG, Koppelman MH, Lelie PN, Hemert FJ, Boot HJ. Multiple surface antigen mutations in five blood donors with occult hepatitis B virus infection. J Med Virol 2008; 80: 1344-1349 [PMID: 18551607 DOI: 10.1002/jmv.21233]
26. Henke-Gendo C, Amini-Bavil-Olyaee S, Challapalli D, Trautwein C, Deppe H, Schulz TF, Heim A, Tacke F. Symptomatic hepatitis B virus (HBV) reactivation despite reduced viral fitness is associated with HBV test and immune escape mutations in an HIV-coinfected patient. J Infect Dis 2008; 198: 1620-1624 [PMID: 18847320 DOI: 10.1086/592987]
27. Sugauchi F, Tanaka Y, Kusumoto S, Matsuura K, Sugiyama M, Kurbanov F, Ueda R, Mizokami M. Virological and clinical characteristics on reactivation of occult hepatitis B in patients with hematological malignancy. J Med Virol 2011; 83: 412-418 [PMID: 21264861 DOI: 10.1002/jmv.21995]